Literature DB >> 28870948

Neoadjuvant Imatinib Therapy Followed by Intersphincteric Resection for Low Rectal Gastrointestinal Stromal Tumors.

Manabu Kaneko1, Hiroaki Nozawa2, Shigenobu Emoto2, Koji Murono2, Kazuhito Sasaki2, Kensuke Otani2, Takeshi Nishikawa2, Toshiaki Tanaka2, Tomomichi Kiyomatsu2, Keisuke Hata2, Kazushige Kawai2, Toshiaki Watanabe2.   

Abstract

BACKGROUND/AIM: Intersphincteric resection (ISR) aims to preserve anal function in patients with very low rectal tumors. Here, we analyzed patients who underwent neoadjuvant imatinib therapy followed by ISR for low rectal gastrointestinal stromal tumors (GISTs). PATIENTS AND METHODS: We retrospectively analyzed patients with low rectal GISTs who underwent neoadjuvant imatinib therapy and ISR between January 2013 and December 2015 at the University of Tokyo hospital.
RESULTS: The study included 4 men and 1 woman, with a median age of 67 years (range=45-67). All patients received 400 mg of neoadjuvant imatinib once daily for the median duration of 4 months (range=3-12). Microscopically, R0 resection was performed in 4 patients, and R1, in 1 patient. There was 1 recurrence event during the median follow-up duration of 35 months.
CONCLUSION: Neoadjuvant imatinib therapy and ISR for low rectal GISTs is a challenging, but promising, alternative to achieve complete resection margins and preserve anal function. Copyright
© 2017, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Gastrointestinal stromal tumor; imatinib; low rectum; neoadjuvant therapy

Mesh:

Substances:

Year:  2017        PMID: 28870948     DOI: 10.21873/anticanres.11936

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  4 in total

Review 1.  Neoadjuvant imatinib therapy in rectal gastrointestinal stromal tumors.

Authors:  Manabu Kaneko; Shigenobu Emoto; Koji Murono; Hirofumi Sonoda; Masaya Hiyoshi; Kazuhito Sasaki; Yasutaka Shuno; Takeshi Nishikawa; Toshiaki Tanaka; Keisuke Hata; Kazushige Kawai; Hiroaki Nozawa
Journal:  Surg Today       Date:  2018-11-15       Impact factor: 2.549

2.  Neoadjuvant tyrosine kinase inhibitors in rectal gastrointestinal stromal tumours: a provision for enhanced oncological and functional outcomes.

Authors:  Zachary Zihui Yong; Jolene Si Min Wong; Melissa Ching Ching Teo; Claramae Shulyn Chia; Chin-Ann Johnny Ong; Mohamad Farid; Grace Hwei Ching Tan
Journal:  Int J Clin Oncol       Date:  2021-02-02       Impact factor: 3.402

3.  Efficacy and safety of neoadjuvant imatinib therapy for patients with locally advanced rectal gastrointestinal stromal tumors: A multi-center cohort study.

Authors:  Weihao Li; Xinyue Li; Kun Yu; Binyi Xiao; Jianhong Peng; Rongxin Zhang; Lingfang Zhang; Kun Wang; Zhizhong Pan; Cong Li; Xiaojun Wu
Journal:  Front Pharmacol       Date:  2022-09-27       Impact factor: 5.988

4.  Preoperative imatinib and laparoscopic intersphincteric resection for large rectal gastrointestinal stromal tumor: A case report.

Authors:  Shinnosuke Nagano; Norikatsu Miyoshi; Tsuyoshi Takahashi; Hiroaki Itakura; Shiki Fujino; Takayuki Ogino; Hidekazu Takahashi; Mamoru Uemura; Chu Matsuda; Tsunekazu Mizusima; Masaki Mori; Yuichiro Doki
Journal:  Int J Surg Case Rep       Date:  2020-05-23
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.